Patients and interested public

Risks and Benefits

Current treatment of AMD can be unsatisfying, due to frequency of injections, which necessitates regular visits to the clinic. The TargetAMD treatment aims at only one 1‑hour surgical session to deliver a safe and life-long solution that results in a comfortable and cost-efficient curative treatment.

Our approach offers:

Lowered costs: Only one dose of current AMD drugs used costs about 1,000 € exclusive the cost for the medical act performed by the ophthalmologist. If one considers that about 8 injections per year are needed, the current yearly drug costs are about 8,000 € per year for the life of the patients plus costs for every injection itself. Our treatment just requires one drug dose which will cost about 3,500 € plus costs for one injection.
Safe: The Sleeping Beauty transposon system used to multiply therapeutic genes, has been shown as an efficient, stable, and safe method.
As in any surgical procedure, adverse effects, although rare, can occur. Potential adverse effects particular for our approach can happen during the puncture of the iris to harvest cells, which can cause blood accumulation and lead to elevation of intraocular pressure that can be treated pharmaceutically, or in severe cases, surgically. Other exceedingly rare adverse effects could be glare, diplopia or mispositioning of an existing intraocular lens or similar implant.
Improvement of quality of life: A unique life-long-acting injection of our product will prevent patients from having repeated distressing visits to the clinic; thus, ease compliance to the treatment. Preserved, and hopefully improved vision will positively affect psychological health and functional status of patients, keeping them mobile, independent and active.

Risks and Be­ne­fits

Risks and Benefits